Indication
Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).
Loading your page…
Loading your page…
Multiple Myeloma
Marketing Authorisation Holder: Bristol-Myers Squibb Pharma EEIG
EMA Authorisation: 11/05/2016
INN: elotuzumab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Empliciti: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.